drugset / Trial / NCT01935453
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer
Phase 1
Completed
18 enrolled
OrienGene Biotechnology Ltd.
Beijing Bozhiyin T&S Co., Ltd. · collabSTART Shanghai · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer.
Timeline
- Start
- 2012-05
- Primary completion
- 2014-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OrienX010 | Unknown | 1e+06 unknown | Intrathecal |
| Subject | OrienX010 | Unknown | 1e+07 unknown | Intrathecal |
| Subject | OrienX010 | Unknown | 1e+08 unknown | Intrathecal |
| Subject | OrienX010 | Unknown | 4e+08 unknown | Intrathecal |